MetAi

For clinics

Medical WeightlossLean mass monitoring, GLP-1 outcomes
Longevity & Hormonal HealthBiological age, longitudinal tracking
TRT / HRT ClinicsHormone response, tissue tracking
Wellness ClinicBefore/after data, patient retention
Fitness & PerformanceAthlete analytics, trainer tools

For enterprise

Insurers & Health PlansShared savings, adherence data
Employers & BenefitsPEPM model, claims reduction
Pharmaceutical CompaniesReal-world evidence, RWE dataset
Pharmacy & Retail HealthDispensing channel, data plan upsell
HomeHow It WorksScienceDevices
Science

Metabolic health is not a number.
It is a continuous story
told in signals physicians rarely see.

The published evidence is unambiguous: poor metabolic health drives the majority of premature death and lost healthspan globally — and most of the clinical signals that predict it accumulate silently between appointments. Weight is a proxy. Body composition, bloodwork trends, and biometrics are the real story. MetAi is built to surface it, continuously, for the physicians who can act on it.

Metabolic disease burden · GBD Study 2021 · eClinicalMedicine · 2024
74.7%
Of diseases listed in the Global Burden of Disease study have a positive association with obesity and metabolic dysfunction. Metabolic disease is not a niche problem — it is the dominant driver of global non-communicable disease burden.
Global Burden of Disease Study 2021 · eClinicalMedicine · 2024
Lean tissue loss · Prado CM et al. · Lancet D&E · 2024
25–39%
Of total weight lost in GLP-1 clinical trials is skeletal muscle and lean tissue — not fat. Without body composition monitoring, physicians cannot distinguish fat loss from muscle loss. The two look identical on a scale.
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB · Lancet Diabetes Endocrinol · 2024
Treatment continuity · SURMOUNT-4 · JAMA · 2024
89.5%
Of weight loss maintained by patients who continued tirzepatide treatment versus near-complete reversal in those who stopped. Continuity of physician-led care — not the drug alone — is what determines whether outcomes hold.
Aronne LJ, Sattar N, Horn DB, Bays HE et al. · JAMA · 2024
The bigger picture

Metabolic health is the upstream variable.
Everything else follows.

We have spent decades treating the downstream consequences of metabolic dysfunction — type 2 diabetes, cardiovascular disease, hypertension, liver disease, sleep apnoea, certain cancers — as separate clinical problems. The published evidence increasingly shows they are expressions of the same upstream failure: a metabolic system that has drifted out of range, undetected, for years before disease is declared.

Obesity is linked to 74.7% of all diseases in the Global Burden of Disease study. It contributes to over 5 million deaths annually. But the number that matters most is not BMI — it is visceral fat accumulation, lean mass trajectory, insulin sensitivity trend, and cardiovascular biomarker drift. These signals are changing every day. The clinical encounter captures a snapshot. What happens between snapshots determines longevity.

The physician-patient relationship that drives real metabolic health — the kind that protects healthspan, preserves muscle, and reduces the risk of the diseases that shorten life — requires continuous shared data. MetAi is the clinical intelligence layer that makes that possible between every appointment.

74.7%
Of GBD-listed diseases have a positive association with obesity and metabolic dysfunction. Metabolic health is the upstream variable — most chronic disease is downstream of it.
Global Burden of Disease Study 2021 · eClinicalMedicine · 2024
5M+
Deaths attributed to high body mass index annually worldwide, with two-thirds driven by cardiovascular disease. Metabolic dysfunction shortens healthspan and lifespan in measurable, preventable ways.
GBD 2017 analysis · NEJM 2017 | Chew et al. · Cell Metabolism · 2023
Only 20%
Of overweight individuals can successfully lose and sustain ≥10% of initial body weight. Without continuous physician-led partnership — backed by real clinical data — outcomes do not hold.
Oxford Academic · Family Practice · 2020

“Muscle mass and strength predict longevity more reliably than BMI. Older adults with greater muscle mass and grip strength consistently live longer and enjoy better functional independence — making lean tissue preservation a longevity intervention, not a cosmetic one.”

Healthspan Research Review · Muscle–Longevity Connection · 2025
Three clinical signal domains

What the metabolic health story is actually made of

Weight is a proxy for three underlying clinical realities that physicians need to see directly — and that change continuously between every appointment. Each domain tells a different chapter of the metabolic health story. Together they define whether a patient's trajectory is heading toward longevity or away from it.

Domain 01
Body composition — lean mass, visceral fat, and the metabolic signals that weight conceals
Weight tells you how much. Body composition tells you of what. Lean tissue mass is the primary driver of metabolic rate, glucose disposal, and functional independence with age. Visceral fat — not subcutaneous fat — is the adipose compartment causally linked to insulin resistance, cardiovascular disease, type 2 diabetes, and all-cause mortality. A scale measures neither. Body composition measurement does.
Published finding · Visceral fat & mortality
Causal
The relationship between visceral fat and longevity is causal, not correlational. Epidemiological evidence links visceral fat to insulin resistance, T2D, cardiovascular disease, stroke, metabolic syndrome, and death — with the association strengthening with cumulative exposure over time.
PubMed meta-analysis · "Should visceral fat be reduced to increase longevity?" · 2013 Liu Q et al. · Journal of Cachexia, Sarcopenia & Muscle · 2025

MetAi responds with MetRX: 8-electrode bioimpedance analysis at home, daily. 25+ metrics — lean mass, visceral fat index, skeletal muscle mass, body fat %, metabolic rate — stream automatically to the physician dashboard. Physicians see the tissue composition story, not just the weight number.

Domain 02
Biometrics — the cardiovascular and sleep signals that precede clinical events by weeks
Heart rate variability reflects autonomic nervous system function and physiological resilience — declining with metabolic stress, sleep disruption, and cardiovascular risk long before symptoms appear. Resting heart rate, SpO₂, and sleep architecture are equally sensitive early indicators. These signals respond to dietary changes, medication effects, and metabolic dysfunction in ways that clinical appointments, taken every four to six weeks, structurally cannot capture.
Published finding · Sleep & metabolic health
2.42×
Increased risk of sarcopenia in individuals with long sleep disorders, per adjusted Cox regression over 8+ years of follow-up. Sleep architecture is not a wellness metric — it is a clinical indicator of metabolic and musculoskeletal trajectory.
ALEXANDROS Longitudinal Study · BMC · 2024 (HR=2.42, 95% CI 1.20–4.91)

MetAi responds with MetWear: Continuous HR, HRV, SpO₂, skin temperature, and sleep staging — wrist strap (Q3 2026) and ring (Q4 2026). When autonomic or cardiovascular signals deteriorate between appointments, the MetAi physician dashboard surfaces the trend before the patient reports a symptom.

Domain 03
Bloodwork trends — the metabolic trajectory visible in labs before symptoms declare
Fasting glucose, HbA1c, lipid fractions, inflammatory markers, liver enzymes, and hormone panels are among the most sensitive indicators of metabolic trajectory. They trend before disease is declared, respond to treatment weeks before weight changes, and reverse — alongside clinical improvements — when continuity of care is withdrawn. Interpreting these values as isolated data points at each visit misses the directional story that matters for longevity.
Published finding · Bloodwork & longevity
Predictive
Blood biomarkers of atherosclerosis, metabolism, inflammation, and insulin resistance are independently associated with longevity — and their trends track closely with dietary intervention and metabolic treatment response. Lab trends are a longevity signal, not just a disease screen.
JAMA 2024 · Mediterranean diet biomarker study · Life Extension Review · 2025

MetAi responds with MedLens: AI-interpreted lab results with automatically calculated clinical indices — ASCVD risk, CKD-EPI, AHI, MELD-Na — integrated alongside body composition and biometric data. Lab trends are contextualised across every available signal, giving physicians the complete metabolic trajectory before every consultation.

Published research

The evidence base
MetAi is built on

MetAi is grounded in peer-reviewed literature across metabolic health, longevity medicine, body composition science, biometric monitoring, and behaviour change. Every signal we track, every alert threshold, and every clinical protocol traces back to a specific published finding.

Lancet D&E
Lancet Diabetes & Endocrinology · 2024
Muscle matters: the effects of medically induced weight loss on skeletal muscle
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB

25–39% of GLP-1 trial weight loss is lean tissue, not fat. Without body composition monitoring, this is entirely invisible. Establishes daily BIA as a clinical necessity — not optional — in physician-supervised metabolic medicine.

Foundation for MetRX daily monitoring protocol
DOM
Diabetes, Obesity & Metabolism · 2022
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, Van Gaal LF et al.

~⅔ of semaglutide weight loss regained within 12 months of stopping, alongside full reversal of cardiometabolic improvements. Physician-led monitoring cannot end when the prescription begins.

Defines the clinical continuity gap MetAi addresses
JAMA
JAMA · 2024
Continued treatment with tirzepatide for maintenance of weight reduction: the SURMOUNT-4 randomized clinical trial
Aronne LJ, Sattar N, Horn DB, Bays HE, Riesmeyer JS et al.

89.5% of weight loss maintained with continued tirzepatide versus near-complete reversal on placebo. Outcomes are a function of continuity — the scientific foundation for MetAi's ongoing care model.

SURMOUNT-4 is the model MetAi's retention architecture is built around
BMC
BMC Public Health · 2024
Leveraging continuous glucose monitoring as a catalyst for behaviour change: a scoping review
Jospe MR, Richardson KM, Saleh AA, Bohlen LC, Crawshaw J, Liao Y et al.

Continuous biological feedback — not periodic measurement — is the primary mechanism of sustained dietary and activity behaviour change across 31 RCTs. Validates MetAi's always-on monitoring architecture over snapshot-based approaches.

Validates daily monitoring frequency across all MetAi hardware
JCSM
Journal of Cachexia, Sarcopenia & Muscle · 2025
Association of cumulative visceral fat exposure with cardiovascular disease and all-cause mortality: a prospective cohort study
Liu Q, Cui H, Si F, Wu Y, Yu J · Kailuan Study cohort

Cumulative exposure to high visceral fat — sustained over years — is independently associated with increased cardiovascular disease and all-cause mortality risk. Visceral fat is a longitudinal longevity metric, not a snapshot — the case for MetRX's daily visceral fat tracking.

Establishes visceral fat trend monitoring as a longevity clinical standard
eClinMed
eClinicalMedicine (The Lancet) · 2026
Trajectory of weight regain after cessation of GLP-1 receptor agonists: systematic review and nonlinear meta-regression
Systematic review · PROSPERO-registered · Search through August 2025

Weight regain post-GLP-1 cessation is rapid, consistent, and population-wide — independent of drug, dose, and treatment duration. Confirms the need for structured monitoring protocols through and beyond GLP-1 treatment.

Informs MetAi's GLP-1 discontinuation and off-ramp monitoring
Healthspan 2025
Healthspan Research Review · 2025
The Muscle–Longevity Connection: the science of preserving muscle with age
Synthesised review · gethealthspan.com · September 2025

Muscle mass and grip strength predict longevity more reliably than BMI. Sarcopenia correlates with faster progression on biological aging clocks. Lean mass preservation in metabolic treatment is a longevity intervention — not a cosmetic consideration.

Frames MetRX lean mass monitoring as a longevity clinical tool
Fam Practice
Family Practice · Oxford Academic · 2020
Patient-centredness and behaviour change for weight loss in physician-led care
Oxford Academic

Only 20% of overweight individuals successfully sustain ≥10% weight loss — and those who do overwhelmingly succeed within a continuous, individualised physician-led partnership. The evidence base for Metamed's clinical model and MetAi's physician-first design.

Scientific foundation for Metamed's physician partnership-first care model
Where MetAi fits

From evidence to clinical platform

Every module in MetAi maps directly to a clinical signal gap identified in the published literature. This is not a wellness app retrofitted for clinical use. Each design decision — every signal tracked, every alert threshold, every integration — traces back to a specific finding about what physicians need to see between appointments to manage metabolic health and longevity outcomes.

Body composition · MetRX
Daily BIA — lean mass, visceral fat, and the tissue story weight conceals
8-electrode segmental bioimpedance analysis at home, every morning. 25+ clinical metrics stream automatically to the physician dashboard — lean mass trajectory, visceral fat index, skeletal muscle mass, metabolic rate. The tissue composition story, not the number on a scale.
Why the science demands itPrado et al. (Lancet D&E, 2024) showed up to 39% of GLP-1 weight loss is lean tissue — invisible without monitoring. Liu et al. (JCSM, 2025) showed cumulative visceral fat exposure causally drives CVD and mortality.
Biometrics · MetWear
Continuous HR, HRV, SpO₂ and sleep — the signals that precede clinical events
MetWear Strap and Ring track cardiovascular and autonomic signals continuously between appointments. HRV, resting heart rate, sleep staging, and skin temperature respond to metabolic treatment, medication, and lifestyle — often weeks before clinical presentation. When the signal deteriorates, the physician sees it first.
Why the science demands itJospe et al. (BMC Public Health, 2024) showed continuous biometric feedback — not periodic measurement — is the primary mechanism of sustained behaviour change. Sleep disorders independently predict sarcopenia (ALEXANDROS Study, 2024).
Lab intelligence · MedLens
AI-interpreted bloodwork — clinical indices calculated, trends contextualised
MedLens integrates lab results into the MetAi physician dashboard with AI-calculated clinical indices — ASCVD risk, CKD-EPI, AHI, MELD-Na — automatically derived from standard panels. Lab values are contextualised alongside body composition and biometric trends, so physicians see the full metabolic trajectory at every consultation, not isolated numbers.
Why the science demands itSTEP 1 Extension (Wilding et al., 2022) showed every cardiometabolic lab marker reverses alongside weight regain. JAMA 2024 biomarker study showed lab trends predict longevity independently. Trends matter more than snapshots.
Clinical notes · MetAi Scribe
AI-generated, evidence-validated clinical notes — from consultation to record in seconds
MetAi Scribe captures the clinical consultation in real time, generating structured, evidence-validated notes (SOAP, Progress, Referral, Intake, Rx) in under 10 seconds. Every recommendation is checked against published guidelines — CMAJ, ACC/AHA, ESC, WHO — with a claim-by-claim evidence score before the note enters the patient record.
Why the science demands itPhysician-led continuity of care is the primary predictor of sustained metabolic outcomes (Oxford Academic, 2020). Evidence-validated notes close the loop between the data MetAi surfaces and the clinical decisions that determine patient trajectory.
The clinical loop

How continuous data becomes
sustainable metabolic health

The published evidence is clear that episodic care cannot produce durable metabolic outcomes. MetAi creates the continuous physician-patient data loop that the research demands — so the 364 days between appointments become part of the clinical record, not a gap in it. Every step in the loop is grounded in published science.

→
Step 01
Patient generates signal — daily
Daily MetRX body composition. Continuous MetWear biometrics — HR, HRV, SpO₂, sleep. Periodic lab panels processed by MedLens. Up to 365 clinical data points per year instead of 4 to 6.
Closes the 364-day gap identified in STEP 1 Extension (2022) where GLP-1 outcomes break down. Addresses the continuity deficit documented across metabolic and longevity medicine literature.
→
Step 02
MetAi surfaces what matters
AI synthesis of body composition trends, biometric signals, and lab trajectories — contextualised together. Clinically meaningful patterns emerge from noise. Physicians see what requires attention before it requires intervention.
Enables early protocol adjustment before lean mass loss or visceral fat accumulation becomes clinically significant — the intervention Prado et al. (2024) and Liu et al. (2025) identify as necessary.
→
Step 03
Physician acts with full clinical context
Pre-consultation MetAi brief. Evidence-validated notes from MetAi Scribe. Protein targets, exercise protocols, dosing, and medication decisions made on actual tissue-level trends — not recalled weight from three weeks ago.
Physician-led continuous partnership validated by Oxford Academic (Family Practice, 2020) as the primary predictor of sustained metabolic health outcomes over the long term.
Step 04
Patient sees progress — and stays
Patients who see daily evidence of lean mass preservation, visceral fat reduction, and improving biometric trends stay engaged — even when the scale hasn't moved. Continuous feedback is the behaviour change mechanism.
Continuous biological feedback validated as the mechanism of sustained behaviour change across chronic metabolic disease populations (Jospe et al., BMC Public Health, 2024).
A note on our own data

Metamed Health is an early-stage physician-led clinical operator. We do not yet have a published internal outcomes dataset. Every statistic on this page is sourced directly from peer-reviewed literature — cited with full authorship, journal, and year. We will share our own outcomes data transparently as it matures under our clinical programme.

The research above reflects the evidence base that informed how we designed MetAi — not marketing claims. If you would like to review any of the full papers referenced here, please contact us: science@metai.health

Get started

Built on the evidence.
Designed for your practice.

See how MetAi translates the published evidence into a daily clinical workflow — body composition, lab intelligence, biometrics, and evidence-validated notes unified in one physician dashboard.

View platform overview

Health intelligence for health partners

The clinical synthesis layer for metabolic and behavioral medicine. Body composition, biometrics, nutrition, and lab intelligence — synthesized in one brain.

Metamed Health →MetWare.Ai →

Solutions

  • Medical Weightloss
  • Longevity
  • Wellness Clinic
  • Fitness & Performance
  • Insurers
  • Employers
  • Pharma
  • Pharmacy

Platform

  • How It Works
  • Devices
  • Science
  • partners@metai.health

Company

  • Metamed Health
  • MetWare.Ai
  • Contact
  • Privacy Policy
  • Terms of Service
MetAi
© 2026 MetAi Health Inc.

MetAi is a clinical intelligence platform — not a substitute for in-person medical judgement.